Literature DB >> 25083249

Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy.

Luke E Grzeskowiak1, Andrew L Gilbert2, Janna L Morrison3.   

Abstract

To date, the investigation of teratogenic effects of medications has largely focused on physical alterations present at birth (i.e. malformations) as opposed to functional alterations (i.e. neurodevelopment, metabolic function) that may not be apparent at birth but could influence an individual's health and risk of disease in later life. The use of routinely collected health data represents one approach to better identifying, quantifying, and understanding the long-term risks or benefits of medication use during pregnancy. As such, the objective of this review was to identify and explore opportunities and challenges associated with using routinely collected health data to examine long-term effects of medication use during pregnancy. Drawing on published research several key methodological issues associated with their use in investigating long-term outcomes are reviewed. While significant opportunities exist to make greater use of routinely collected health data, there are a number of key challenges. Identified challenges relate to aspects of study design and analysis, and include obtaining access to data, the ability to match records across datasets and over long periods of time, how medication exposures are ascertained and classified, issues around loss to follow-up how outcomes are ascertained and classified, and the careful interpretation of results in light of study and data limitations. Understanding key challenges associated with using routinely collected health data to investigate long-term effects of medication use during pregnancy is essential in supporting their appropriate use and interpretation, which will contribute to improving the quality of research undertaken and ensure the reliability of results obtained.

Keywords:  data linkage; medication; pharmacovigilance; pregnancy; teratogen

Year:  2013        PMID: 25083249      PMCID: PMC4110818          DOI: 10.1177/2042098612470389

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  42 in total

1.  Systematic identification of drugs that cause birth defects--a new opportunity.

Authors:  Allen A Mitchell
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

Review 2.  Investigating outcomes associated with medication use during pregnancy: a review of methodological challenges and observational study designs.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Reprod Toxicol       Date:  2012-02-04       Impact factor: 3.143

Review 3.  Methodological issues in the epidemiological study of the teratogenicity of drugs.

Authors:  Bengt A J Källén
Journal:  Congenit Anom (Kyoto)       Date:  2005-06       Impact factor: 1.409

4.  Early diagnoses of autism spectrum disorders in Massachusetts birth cohorts, 2001-2005.

Authors:  Susan E Manning; Carol A Davin; Wanda D Barfield; Milton Kotelchuck; Karen Clements; Hafsatou Diop; Tracy Osbahr; Lauren A Smith
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

5.  Population-based linkage of health records in Western Australia: development of a health services research linked database.

Authors:  C D Holman; A J Bass; I L Rouse; M S Hobbs
Journal:  Aust N Z J Public Health       Date:  1999-10       Impact factor: 2.939

6.  Creating a population-based linked health database: a new resource for health services research.

Authors:  R Chamberlayne; B Green; M L Barer; C Hertzman; W J Lawrence; S B Sheps
Journal:  Can J Public Health       Date:  1998 Jul-Aug

7.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

8.  Effect of treatment of gestational diabetes mellitus on obesity in the next generation.

Authors:  Matthew W Gillman; Helena Oakey; Peter A Baghurst; Robert E Volkmer; Jeffrey S Robinson; Caroline A Crowther
Journal:  Diabetes Care       Date:  2010-02-11       Impact factor: 19.112

9.  Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight.

Authors:  L E Grzeskowiak; A L Gilbert; J L Morrison
Journal:  J Dev Orig Health Dis       Date:  2012-08       Impact factor: 2.401

10.  The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy.

Authors:  Helle Kieler
Journal:  Clin Epidemiol       Date:  2010-10-21       Impact factor: 4.790

View more
  6 in total

Review 1.  Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy.

Authors:  Thomas M Polasek; Matthew P Doogue; Tilenka R J Thynne
Journal:  Ther Adv Drug Saf       Date:  2018-04-25

Review 2.  Linking databases on perinatal health: a review of the literature and current practices in Europe.

Authors:  M Delnord; K Szamotulska; A D Hindori-Mohangoo; B Blondel; A J Macfarlane; N Dattani; C Barona; S Berrut; I Zile; R Wood; L Sakkeus; M Gissler; J Zeitlin
Journal:  Eur J Public Health       Date:  2016-01-10       Impact factor: 3.367

Review 3.  Underutilisation of routinely collected data in the HIV programme in Zambia: a review of quantitatively analysed peer-reviewed articles.

Authors:  Tendai Munthali; Patrick Musonda; Paul Mee; Sehlulekile Gumede; Ab Schaap; Alwyn Mwinga; Caroline Phiri; Nathan Kapata; Charles Michelo; Jim Todd
Journal:  Health Res Policy Syst       Date:  2017-06-13

4.  Medication history-wide association studies for pharmacovigilance of pregnant patients.

Authors:  Anup P Challa; Xinnan Niu; Etoi A Garrison; Sara L Van Driest; Lisa M Bastarache; Ethan S Lippmann; Robert R Lavieri; Jeffery A Goldstein; David M Aronoff
Journal:  Commun Med (Lond)       Date:  2022-09-16

5.  Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.

Authors:  Shu-Chen Chien; Shuo-Ming Ou; Chia-Jen Shih; Pei-Wen Chao; Szu-Yuan Li; Yi-Jung Lee; Shu-Chen Kuo; Shuu-Jiun Wang; Tzeng-Ji Chen; Der-Cherng Tarng; Hsi Chu; Yung-Tai Chen
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

6.  A qualitative inquiry into implementing an electronic health record system (SmartCare) for prevention of mother-to-child transmission data in Zambia: a retrospective study.

Authors:  Sehlulekile Gumede-Moyo; Jim Todd; Virginia Bond; Paul Mee; Suzanne Filteau
Journal:  BMJ Open       Date:  2019-09-06       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.